Alexia Letierce - Dissemin

All papers authored by Alexia Letierce

This paper is made freely available by the publisher.

2022 Henry N. Ginsberg, Robert S. Rosenson, G. Kees Hovingh, Alexia Letierce

, Rita Samuel, Yann Poulouin, Christopher P. Cannon

LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

2021 Khalid Alswat

, Elvy Soliman, Isam Salih, Ahmed Bashmail, Alexia Letierce

, Ali Benmousa, Saad Alghamdi, Khalid I. Bzeizi, Saleh A. Alqahtani

, Mohamed Shawkat, Dieter C. Broering, Waleed K. Al-Hamoudi

Long Term Outcomes of Liver Transplantation For Patients With Autoimmune Hepatitis

Upload

2019 Kausik K. Ray, Stefano Del Prato, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce

, Jonas Mandel, Rita Samuel, Maja Bujas-Bobanovic, Lawrence A. Leiter

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Download from link.springer.com

Frederick J. Raal, Jaakko Tuomilehto, Andrei C. Sposito, Francisco A. Fonseca, Maurizio Averna, Michel Farnier, Raul D. Santos, Keith C. Ferdinand, R. Scott Wright, Eliano Pio Navarese, Danielle M. Lerch, Michael J. Louie, L. Veronica Lee, Alexia Letierce

, Jennifer G. Robinson

Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies

Upload

Shaun G. Goodman, Philip E. Aylward, Michael Szarek, Vakhtang Chumburidze, Deepak L. Bhatt, Vera A. Bittner, Rafael Diaz, Jay M. Edelberg, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Sasko Kedev, Alexia Letierce

, Angele Moryusef, Robert Pordy and 7 other authors

Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

Upload

Antonio J. Vallejo-Vaz, Kausik K. Ray

, Henry N. Ginsberg, Michael H. Davidson, Robert H. Eckel, L. Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce

, Christopher P. Cannon

Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control

Upload

Eric Bruckert, Dean J. Kereiakes, Michael J. Koren, Michael J. Louie, Alexia Letierce

, Kathryn Miller, Christopher P. Cannon

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab

Upload

2018 Antonio J. Vallejo‐Vaz, Henry N. Ginsberg, Michael H. Davidson, Robert H. Eckel, Christopher P. Cannon, L. Veronica Lee, Laurence Bessac, Robert Pordy, Alexia Letierce

, Kausik K. Ray

Lower On‐Treatment Low‐Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials

Download from doi.org

L. A. Leiter

, F. J. Tinahones, D. G. Karalis, M. Bujas-Bobanovic, A. Letierce

, J. Mandel, R. Samuel, P. H. Jones

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials

Download from api.wiley.com

Marja-Riitta Taskinen, Stefano Del Prato, Maja Bujas-Bobanovic, Michael J. Louie, Alexia Letierce

, Desmond Thompson, Helen M. Colhoun

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial

Upload

Om P. Ganda

, Jorge Plutzky, Santosh K. Sanganalmath, Maja Bujas-Bobanovic, Andrew Koren, Jonas Mandel, Alexia Letierce

, Lawrence A. Leiter

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials

Download from api.wiley.com

Peter P. Toth, Jamie P. Dwyer, Christopher P. Cannon, Helen M. Colhoun, Daniel J. Rader, Ashish Upadhyay, Michael J. Louie, Andrew Koren, Alexia Letierce

, Jonas Mandel, Maciej Banach

Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease

Upload

Henry N. Ginsberg, Michel Farnier, Jennifer G. Robinson, Christopher P. Cannon, Naveed Sattar, Marie T. Baccara-Dinet, Alexia Letierce

, Maja Bujas-Bobanovic, Michael J. Louie, Helen M. Colhoun

Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies

Download from link.springer.com

Robert R. Henry

, Dirk Müller-Wieland, Pam R. Taub, Maja Bujas-Bobanovic, Michael J. Louie, Alexia Letierce

, Henry N. Ginsberg

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials

Download from api.wiley.com

Kausik K. Ray

, Lawrence A. Leiter

, Dirk Müller-Wieland, Bertrand Cariou, Helen M. Colhoun, Robert R. Henry

, Francisco J. Tinahones, Maja Bujas-Bobanovic, Catherine Domenger, Alexia Letierce

, Rita Samuel, Stefano Del Prato

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial

Download from api.wiley.com

2017 B. Cariou, L. A. Leiter, D. Müller-Wieland, G. Bigot, H. M. Colhoun, S. Del Prato, R. R. Henry, F. J. Tinahones, A. Letierce

, L. Aurand, J. Maroni, K. K. Ray, M. Bujas-Bobanovic

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM–INSULIN trial

Upload

Catherine Martelli, Amélie Petillion, Marine Brunet-Lecomte, Rubén Miranda Marcos

, Sandra Chanraud, Ammar Amirouche, Alexia Letierce

, Nikoleta Kostogianni, Hervé Lemaitre

, Henri-Jean Aubin, Lisa Blecha, Michel Reynaud, Jean-Luc Martinot, Amine Benyamina

Neuropsychological Impairment in Detoxified Alcohol-Dependent Subjects with Preserved Psychosocial Functioning

Download from doi.org

L. A. Leiter

, D. Müller-Wieland, M. T. Baccara-Dinet, A. Letierce

, R. Samuel, B. Cariou

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

Download from api.wiley.com

Dirk Müller-Wieland, Lawrence A. Leiter, Bertrand Cariou, Alexia Letierce

, Helen M. Colhoun, Stefano Del Prato, Robert R. Henry, Francisco J. Tinahones, Lisa Aurand, Jaman Maroni, Kausik K. Ray, Maja Bujas-Bobanovic

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Download from link.springer.com

2016 Jérôme Cros

, Emilie Sbidian, Katia Posseme, Alexia Letierce

, Catherine Guettier, Gérard Benoît, Sophie Ferlicot

Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Alexia Letierce